Skip to main content

$0.125 (0.00%)

High

-

Low

-

Trades

-

Turnover

$0

Volume

0
18 May 2025 at 9:06am
Register to track EMD and receive email alerts.

Preclinical studies initiated for MDMA-inspired analogues

StockBot

416,823 posts

EMD released this announcement to the ASX on 4 August 2022, 9:54. The announcement is marked as price sensitive, and is 4 page(s) in length and 157.16kb in size.

You can view all announcements from EMD and see how they appear on a price chart on the announcements page.

At the date of this announcement, EMD was 0.086% short sold according to ASIC data. It was ranked the 470th most shorted stock on the ASX. It remains ranked 600th as of the latest reported data (17 April 2025).

Other Recent Announcements from EMD
Trading Halt 29 June 2023, 9:33
Emyria Receives Ethics Approval for MDMA-assisted Therapy 8 June 2023, 9:10
Section 708A(5)(e) Notice 10 May 2023, 18:37
Preclinical studies initiated for MDMA-inspired analogues 4 August 2022, 9:54
Appendix 4C - Quarterly 28 July 2022, 11:24
Emyria expands drug candidate library inspired by MDMA 18 July 2022, 8:19
Notification regarding unquoted securities - EMD 9 June 2022, 9:21
You must login or register to post a comment.

You must be logged in to post a reply.

Register to track EMD and receive email alerts.